Cargando…

[1, 8]-Naphthyridine derivatives as dual inhibitor of alkaline phosphatase and carbonic anhydrase

[1,8]-Naphthyridine derivatives have been reported to possess important biological activities and may serve as attractive pharmacophores in the drug discovery process. [1,8]-Naphthyridine derivatives (1a-1l) were evaluated for inhibitory potential for isozymes of carbonic anhydrase (CA) and alkaline...

Descripción completa

Detalles Bibliográficos
Autores principales: Alrokayan, Salman, Hussain, Tajamul, Alamery, Salman, Mohammed, Arif Ahmed, Mahmood, Abid, Ejaz, Syeda Abida, Langer, Peter, Iqbal, Jamshed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10599030/
https://www.ncbi.nlm.nih.gov/pubmed/37880684
http://dx.doi.org/10.1186/s13065-023-01052-8
_version_ 1785125688031838208
author Alrokayan, Salman
Hussain, Tajamul
Alamery, Salman
Mohammed, Arif Ahmed
Mahmood, Abid
Ejaz, Syeda Abida
Langer, Peter
Iqbal, Jamshed
author_facet Alrokayan, Salman
Hussain, Tajamul
Alamery, Salman
Mohammed, Arif Ahmed
Mahmood, Abid
Ejaz, Syeda Abida
Langer, Peter
Iqbal, Jamshed
author_sort Alrokayan, Salman
collection PubMed
description [1,8]-Naphthyridine derivatives have been reported to possess important biological activities and may serve as attractive pharmacophores in the drug discovery process. [1,8]-Naphthyridine derivatives (1a-1l) were evaluated for inhibitory potential for isozymes of carbonic anhydrase (CA) and alkaline phosphatase (ALP). CAs have been reported to carry out reversible hydration of CO(2) into HCO(3)(−), secretion of electrolytes, acid–base regulation, bone resorption, calcification, and biosynthetic reactions. Whereas ALPs hydrolyze monophosphate esters with the release of inorganic phosphate and play an important role in bone mineralization. Both enzymes have been found to be over-expressed and raised functional activities in patients suffering from rheumatoid arthritis. The discovery of dual inhibitors of these enzymes may provide a synergistic effect to cure bone disorders such as rheumatoid arthritis and ankylosing spondylitis. Among the test compounds, the most potent inhibitors for CA-II, CA-IX, and CA-XII were 1e, 1g, and 1a with IC(50) values of 0.44 ± 0.19, 0.11 ± 0.03 and 0.32 ± 0.07 µM, respectively. [1,8]-Naphthyridine derivatives (1a–1l) were approximately 4 folds more potent than standard CA inhibitor acetazolamide. While in the case of ALPs, the most potent compounds for b-TNAP and c-IAP were 1b and 1e with IC(50) values of 0.122 ± 0.06 and 0.107 ± 0.02 µM, respectively. Thus, synthesized derivatives proved to be 100 to 800 times more potent as compared to standard inhibitors of b-TNAP and c-IAP (Levamisole and L-phenyl alanine, respectively). In addition, selectivity and dual inhibition of [1,8]-Naphthyridine derivatives confer precedence over known inhibitors. Molecular docking and molecular simulation studies were also conducted in the present studies to define the type of interactions between potential inhibitors and enzyme active sites. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13065-023-01052-8.
format Online
Article
Text
id pubmed-10599030
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-105990302023-10-26 [1, 8]-Naphthyridine derivatives as dual inhibitor of alkaline phosphatase and carbonic anhydrase Alrokayan, Salman Hussain, Tajamul Alamery, Salman Mohammed, Arif Ahmed Mahmood, Abid Ejaz, Syeda Abida Langer, Peter Iqbal, Jamshed BMC Chem Research [1,8]-Naphthyridine derivatives have been reported to possess important biological activities and may serve as attractive pharmacophores in the drug discovery process. [1,8]-Naphthyridine derivatives (1a-1l) were evaluated for inhibitory potential for isozymes of carbonic anhydrase (CA) and alkaline phosphatase (ALP). CAs have been reported to carry out reversible hydration of CO(2) into HCO(3)(−), secretion of electrolytes, acid–base regulation, bone resorption, calcification, and biosynthetic reactions. Whereas ALPs hydrolyze monophosphate esters with the release of inorganic phosphate and play an important role in bone mineralization. Both enzymes have been found to be over-expressed and raised functional activities in patients suffering from rheumatoid arthritis. The discovery of dual inhibitors of these enzymes may provide a synergistic effect to cure bone disorders such as rheumatoid arthritis and ankylosing spondylitis. Among the test compounds, the most potent inhibitors for CA-II, CA-IX, and CA-XII were 1e, 1g, and 1a with IC(50) values of 0.44 ± 0.19, 0.11 ± 0.03 and 0.32 ± 0.07 µM, respectively. [1,8]-Naphthyridine derivatives (1a–1l) were approximately 4 folds more potent than standard CA inhibitor acetazolamide. While in the case of ALPs, the most potent compounds for b-TNAP and c-IAP were 1b and 1e with IC(50) values of 0.122 ± 0.06 and 0.107 ± 0.02 µM, respectively. Thus, synthesized derivatives proved to be 100 to 800 times more potent as compared to standard inhibitors of b-TNAP and c-IAP (Levamisole and L-phenyl alanine, respectively). In addition, selectivity and dual inhibition of [1,8]-Naphthyridine derivatives confer precedence over known inhibitors. Molecular docking and molecular simulation studies were also conducted in the present studies to define the type of interactions between potential inhibitors and enzyme active sites. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13065-023-01052-8. Springer International Publishing 2023-10-25 /pmc/articles/PMC10599030/ /pubmed/37880684 http://dx.doi.org/10.1186/s13065-023-01052-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Alrokayan, Salman
Hussain, Tajamul
Alamery, Salman
Mohammed, Arif Ahmed
Mahmood, Abid
Ejaz, Syeda Abida
Langer, Peter
Iqbal, Jamshed
[1, 8]-Naphthyridine derivatives as dual inhibitor of alkaline phosphatase and carbonic anhydrase
title [1, 8]-Naphthyridine derivatives as dual inhibitor of alkaline phosphatase and carbonic anhydrase
title_full [1, 8]-Naphthyridine derivatives as dual inhibitor of alkaline phosphatase and carbonic anhydrase
title_fullStr [1, 8]-Naphthyridine derivatives as dual inhibitor of alkaline phosphatase and carbonic anhydrase
title_full_unstemmed [1, 8]-Naphthyridine derivatives as dual inhibitor of alkaline phosphatase and carbonic anhydrase
title_short [1, 8]-Naphthyridine derivatives as dual inhibitor of alkaline phosphatase and carbonic anhydrase
title_sort [1, 8]-naphthyridine derivatives as dual inhibitor of alkaline phosphatase and carbonic anhydrase
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10599030/
https://www.ncbi.nlm.nih.gov/pubmed/37880684
http://dx.doi.org/10.1186/s13065-023-01052-8
work_keys_str_mv AT alrokayansalman 18naphthyridinederivativesasdualinhibitorofalkalinephosphataseandcarbonicanhydrase
AT hussaintajamul 18naphthyridinederivativesasdualinhibitorofalkalinephosphataseandcarbonicanhydrase
AT alamerysalman 18naphthyridinederivativesasdualinhibitorofalkalinephosphataseandcarbonicanhydrase
AT mohammedarifahmed 18naphthyridinederivativesasdualinhibitorofalkalinephosphataseandcarbonicanhydrase
AT mahmoodabid 18naphthyridinederivativesasdualinhibitorofalkalinephosphataseandcarbonicanhydrase
AT ejazsyedaabida 18naphthyridinederivativesasdualinhibitorofalkalinephosphataseandcarbonicanhydrase
AT langerpeter 18naphthyridinederivativesasdualinhibitorofalkalinephosphataseandcarbonicanhydrase
AT iqbaljamshed 18naphthyridinederivativesasdualinhibitorofalkalinephosphataseandcarbonicanhydrase